Total U.S. shipments of COVID-19 molecular diagnostic tests have reached 200 million, according to AdvaMed’s COVID-19 diagnostic supply registry. A breakdown of the data shows that diagnostics companies are shipping, on average, more than 1.4 million molecular tests each day.
“For the past few months, our diagnostics companies have made it clear they’ll do whatever it takes to stay ahead of COVID-19 testing demand to help bring this pandemic under control,” said Scott Whitaker, president and CEO of the medtech trade group. “Two hundred million molecular tests shipped nationwide since the beginning of the pandemic is a remarkable testament to their commitment to saving lives.”
According to the registry, approximately 121 million COVID-19 molecular tests have been administered as of October 10. AdvaMed launched the registry July 21 to aid state and federal pandemic responses.
The AdvaMed registry provides weekly state- and national-level updates on the number of molecular, antigen, and antibody tests shipped in the U.S. AdvaMed and AdvaMedDx, the association’s division of diagnostics companies, developed the registry in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, Qiagen, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers and Thermo Fisher Scientific.
U.S. PCR tests for COVID-19 reached approximately1.2 million and daily infections reached 58,000 as of the morning of Oct. 20, according to UBS. Here’s a breakdown of the monthly trend for PCR tests completed in the U.S.:
- March ~1 million.
- April ~5.2 million.
- May ~10.8 million.
- June ~15.2 million.
- July ~23.1 million.
- August ~22 million.
- September ~23.6 million.
- October projected at ~31.1 million.
This article has been updated with statistics from UBS.